CVS Health Reports Q2 2024 Results and Revises Guidance

Details

GAAP diluted EPS was $1.41, down from $1.48 in Q2 2023, and Adjusted EPS was $1.83, down from $2.21. The company revised its full-year 2024 guidance, lowering GAAP diluted EPS to a range of $4.95 to $5.20 and Adjusted EPS to $6.40 to $6.65. The results were impacted by continued pressure in the Health Care Benefits segment and strong performance in other segments. Management also announced leadership changes in the Health Care Benefits segment.

Items reported

Exhibits (1)

About CVS Health Corporation

CVS Health Corporation is a leading health services company in the United States, offering a comprehensive range of services aimed at improving healthcare accessibility and convenience. Primarily known for its extensive network of pharmacies, CVS Health operates thousands of retail locations nationwide. These outlets provide prescription medications, over-the-counter drugs, health and wellness products, and immunization services. Beyond retail, CVS Health plays a significant role in the healthcare sector through its pharmacy benefit management division, Caremark, which administers prescription drug plans for insurers and employers. Additionally, the company owns Aetna, a major health insurance provider, aligning its services across retail, pharmacy benefits, and insurance solutions to deliver integrated healthcare experiences. With its broad reach and diverse healthcare offerings, CVS Health Corporation holds a critical place in the healthcare market, continuously working to streamline and enhance the delivery of medical services across the country.